SELL & take, page-22

Given the number of holders that are in the process of sell and buy back via Rights Issue I suspect they will get the min. + maybe even something close to the $6M.

Consider this:

Suda as at 31/12/2012

Shares on issue circa: 610,000,000
Share Price: 3.3c
Market Cap: $20.13M
Debt on balance sheet $700,000
HCBP Liability Status: Known and in process of defending the action

Product Pipeline
- ArtiMist in Stage 3 Trials
-Intention to acquire assets of Novel known

Market Cap: $20.13M


----------------------------------------------------------------------------------------------------------

Suda as at 13/07/2018

Share on issue circa: 1.2B
Likely Share Price: 0.5c
Market Cap: $6M
Debt on balance sheet $2M (will be $0 at 31/07/20-18 if CR >$4M as anticipated)
HCBP Liability Status: Resolved with payment plan - $2.5M over 3.5 years

Product Pipeline
- ArtiMist Pending TGA Approval expected end of CY2018
- ZolpiMist Global rights excl. North America. Deals with EddingPharm and Teva
- SUD-001 Advanced Negations to license to Pharma Co in USA
- SUD-003 Deal discussions ongoing
- SUD-004 Discussing development options with potential partners
- SUD-005 In discussions with multiple potential partners to enter global license agreement
-SUD-018 Lab work, potential significant market for product IF proven
-Pfizer OTC still pending decision from Pfizer

Also Teva expect to have marketing approval during Q2 FY19 for Chile which will trigger milestone payment to Suda. Royalties on sales to follow per agreement.

Market Cap: $6M

I believe all of the above is correct. I'm &#$^ at this situation however do think they will get the $4M min. Also getting Teva Chile ZopliMist registered and receiving payment is out of Suda's hands, if they do basically nothing $ will still be heading their way...